Filter By Industry
Filter By Tag

Newsroom

Strategic Guru Press releases

1 - 10 of 170 Press Releases

Mar 26, 2014
Proceeds of Magic: The Gathering Event Will Be Donated to Local Gamer in Need

Oct 16, 2013
Triangle Financial Advisors President Featured in 2014 Woman’s Advantage Calendar

Oct 09, 2013
Cary, NC – Technology Associates has announced that they have been named one of five finalists for the North Carolina Technology Association (NCTA) 21 Awards in the “Best Customer Service Company of the Year” Excellence Awards category.

Sep 25, 2013
President Lorraine Johnson, CFP®, CFA, ADPA®, Announces Next Chapter in Company Growth

May 24, 2012
Niiki Pharma Inc. announced that results from the completed Phase I dose escalation trial of its GRP78 targeted anti-cancer agent, NKP-1339, will be presented at the Annual Meeting of the American Society of Clinical Oncology to be held in Chicago.

Apr 03, 2012
Niiki Pharma announced the presentation of preclinical data at the American Association for Cancer Research Annual Meeting in Chicago, Illinois for its novel compound, NKP-2235, the first highly orally bioavailable gallium-based anti-cancer agent.

Feb 01, 2012
Niiki Pharma announced today the formation of its Scientific Advisory Board. Daniel Haller M.D. will chair the advisory board, and will be joined by Lee Ellis M.D. and Matt Kulke M.D. The Board will provide clinical and strategic guidance.

Jan 18, 2012
Niiki Pharma Inc. announced today that it has completed the dose escalation portion of the Phase I clinical trial of its lead product, NKP-1339, a first-in-class small molecule that down-regulates GRP78, a key tumor survival and anti-apoptosis factor

Nov 15, 2011
An abstract given at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrated NKP-1339’s synergistic activity in both in vitro and in vivo preclinical models with a broad range of anti-tumor agents.

Sep 20, 2011
Phase I clinical trial results of the first-in-class cancer agent show 25% of enrolled patients (six) exhibiting anti-tumor activity for at least 12 weeks. One patient with a carcinoid tumor has tumor regression, continuing on NKP-1339 for 70+ weeks.


Page: 1 2 3 4 5 Next
Strategic Guru RSS Feed